, Singapore

Aqua Munda commits $208m to buy Hyflux's debts

It will also be used for funding the water treatment firm’s capital requirements.

Aqua Munda has committed $208m to fund in buying the embattled water treatment firm Hyflux’s debts from its noteholders and creditors, according to a press release. The firm also extended the deadline for submission of bids from 23 January to 31 January.

The acceptance deadline has also been revised to 3 April. The funding could also be contributed to Hyflux’s working capital requirements.

The funding will also be used for Hyflux’s working capital requirements, if agreed.

This follows after the water firm received an offer from Aqua Munda to buy a portion of its creditors’ debts amounting to about $1.8b last 19 December.

The investor sent an invitation memorandum on 27 December 2019, inviting holders or beneficial owners and creditors holding Eligible Debts to tender their respective Eligible Debts for purchase by Aqua Munda. Interested foreign noteholders were asked to provide an address in Singapore by 27 January.

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare